Table 3 Characteristics of the discontinued cases, categorized into events
The reason of discontinuation of riluzole | n (rate vs. all, %) | Sex (Male, %) | Onset of ALS | Duration from the beginning of riluzole (days, median, IQR) | Duration of ALS at withdrew riluzole (years, median, IQR) | Past histories (n) |
|---|---|---|---|---|---|---|
Age (years old, median, IQR) | ||||||
Elevated liver enzymes | 5 (5.4) | 80 | 65 (56–67) | 11 (7.3–14) | 1 (1–2) | Diabetes/HT/HL (4), Reflux esophagitis (1), Heavy drinker (1) |
IP | 4 (4.3) | 50 | 65.5 (55–73.3) | 60 (48.5–82.5) | 2 (1.8–2.5) | past smoker (2) |
Appetite loss / Nausea | 3 (3.3) | 33 | 64 (62–71) | 2 (2–5.5) | 3 (2–4) | Depressive status (2) |
Dizziness | 2 (2.2) | 50 | 69 (66–72) | 4 and 90–120, respectively | 2 and 20 years, respectively | |
General malaise | 1 (1.1) | 0 | 67 | 90 | 3 | |
Paresthesia of tongue | 1 (1.1) | 100 | 53 | 180 | 1 | Psoriasis vulgaris |
Urinary urgency | 1 (1.1) | 100 | 70 | 0–3 | 2 |